These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 17116133)

  • 1. Cytomegalovirus infection in renal transplant recipients.
    Carstens J; Andersen HK; Spencer E; Madsen M
    Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
    Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
    Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gancyclovir prophylaxis in high risk patients.
    Campino A
    Transplant Proc; 2005 Dec; 37(10):4311-2. PubMed ID: 16387106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N; Wannstedt C; Keyes L; Wagener MM; Cacciarelli TV
    Liver Transpl; 2005 Jun; 11(6):700-4. PubMed ID: 15915496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
    Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
    Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary cytomegalovirus infection after combined cadaveric transplantation of the liver and kidney].
    Slavicek J; Puretić Z; Glavas-Boras S; Smalcelj R; Barisić I; Vuković J; Seso-Simić D; Slavicek V; Humar I; Kes P
    Acta Med Croatica; 2003; 57(1):87-90. PubMed ID: 12876872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
    Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients.
    Renoult E; Clermont MJ; Phan V; Buteau C; Alfieri C; Tapiero B
    Pediatr Transplant; 2008 Jun; 12(4):420-5. PubMed ID: 18466427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of antigenemia assay in the early diagnosis and treatment of CMV infection in renal transplant patients.
    Chiaramonte S; Pellizzer G; Rassu M; Dissegna D; Bragantiini L; Zuccarotto D; La Greca G
    Clin Nephrol; 2000 Apr; 53(4):suppl 10-2. PubMed ID: 10809428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of viral load and antigenemia as markers for relapse cytomegalovirus infection in renal transplant recipients].
    Franco A; Serrano R; Gimeno A; de Juan J; Merino E; Jiménez del Cerro L; Olivares J
    Nefrologia; 2007; 27(2):202-8. PubMed ID: 17564566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.
    Haririan A; Morawski K; West MS; El-Amm JM; Doshi MD; Cincotta E; Alangaden GJ; Chandrasekar P; Gruber SA
    Clin Transplant; 2007; 21(4):466-71. PubMed ID: 17645705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation.
    Lianghui G; Shusen Z; Tingbo L; Yan S; Weilling W; Anwei L
    Transplant Proc; 2004 Jun; 36(5):1502-5. PubMed ID: 15251371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
    Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection.
    Christmas SE; Halliday D; Lawton N; Wang H; Abdalla I; Masters J; Hassan RL; Hart IJ; Khan N; Smith J; Hammad A; Bakran A
    Transpl Immunol; 2009 Dec; 22(1-2):99-104. PubMed ID: 19635559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus.
    Mikulska M; Raiola AM; Bruzzi P; Varaldo R; Annunziata S; Lamparelli T; Frassoni F; Tedone E; Galano B; Bacigalupo A; Viscoli C
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):92-9. PubMed ID: 21689774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.